Screener
Gilead Sciences GILD Other — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Gilead Sciences’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:13 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000882095-26-000031
| (in millions) | Three Months Ended June 30, 2026 / U.S. | Three Months Ended June 30, 2026 / Europe | Three Months Ended June 30, 2026 / Rest of World | Three Months Ended June 30, 2026 / Total | Three Months Ended June 30, 2025 / U.S. | Three Months Ended June 30, 2025 / Europe | Three Months Ended June 30, 2025 / Rest of World | Three Months Ended June 30, 2025 / Total |
|---|---|---|---|---|---|---|---|---|
| Total Oncology | 468 | 265 | 140 | 873 | 427 | 291 | 131 | 849 |
| Other | ||||||||
| AmBisome | 4 | 47 | 59 | 110 | 7 | 65 | 56 | 129 |
| Other(5) | 22 | 8 | 21 | 51 | 44 | 8 | 21 | 73 |
| Total Other | 26 | 55 | 80 | 161 | 52 | 73 | 77 | 202 |
| Total product sales | 5,601 | 1,155 | 872 | 7,627 | 5,038 | 1,178 | 838 | 7,054 |
| Royalty, contract and other revenues | 2 | 169 | 4 | 176 | 13 | 10 | 4 | 27 |
| Total revenues | $5,603 | $1,324 | $876 | $7,803 | $5,051 | $1,189 | $842 | $7,082 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Gilead Sciences's other — total revenues?
- Gilead Sciences (GILD) reported other — total revenues of $51M in Q2 2026.
- How has Gilead Sciences's other — total revenues changed year-over-year?
- Gilead Sciences's other — total revenues decreased by 30.1% year-over-year, from $73M to $51M.
- What is the long-term trend for Gilead Sciences's other — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's other — total revenues has grown at a 0.8% compound annual growth rate (CAGR), from $281M to $290M.
- What does other — total revenues mean?
- This metric represents the aggregate gross revenue generated from products or services that fall outside the company's primary therapeutic focus areas, such as HIV, liver disease, or oncology. It captures the financial contribution of legacy products, niche therapies, or ancillary business lines that do not meet the threshold for individual segment reporting. Monitoring this revenue stream helps investors assess the performance of non-core assets and the company's ability to monetize secondary product portfolios.
Ask your AI about Gilead Sciences's other — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude